Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Smith C.C.Levis M.J.Perl A.E.Martinelli G.Neubauer A.Berman E.Montesinos P.Baer M.R.Larson R.A.WEN-CHIEN CHOUYokoyama H.Recher C.Yoon S.-S.Hill J.E.Rosales M.Bahceci E.2021-02-052021-02-0520191528-0020https://scholars.lib.ntu.edu.tw/handle/123456789/548638Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trialjournal article10.1182/blood-2019-122620317239842-s2.0-85074960391